首页> 外文期刊>Journal of Immunological Methods >Flow cytometry-based biomarkers in translational medicine and drug development.
【24h】

Flow cytometry-based biomarkers in translational medicine and drug development.

机译:基于流式细胞仪的生物标志物在转化医学和药物开发中的应用。

获取原文
获取原文并翻译 | 示例
       

摘要

The objective of the translational medicine approach is toaccelerate the practical applications of biomedical discoveriesfrom “bench-to-bedside,” thus advancing both basic andclinical research. The success of translational medicinedepends upon an open, bi-directional exchange of informationamong research scientists, clinical scientists, and pharmaceuticalscientists.The translational medicine approach is now routinelyapplied during drug development in order to increase thesuccess rate, and decrease the timelines and costs associatedwith delivering novel therapeutics. Examples of the translationalmedicine approach are evident at each stage of the drugdevelopment lifecycle: drug discovery, toxicological assessment,and clinical evaluation. For example, the molecularpathways and mechanistic origins of diseases identified inresearch laboratories are translated into molecular targets fornovel therapeutics during the drug discovery phase.
机译:转化医学方法的目标是从“从台到床”加速生物医学发现的实际应用,从而推进基础研究和临床研究。翻译医学的成功取决于研究科学家,临床科学家和药物科学家之间的开放,双向信息交流。现在,在药物开发过程中通常采用转化医学方法,以提高成功率,并减少与交付新颖药物有关的时间表和成本。疗法。在药物开发生命周期的每个阶段,都有明显的转化医学方法的例子:药物发现,毒理学评估和临床评估。例如,在药物发现阶段,将在研究实验室中鉴定出的疾病的分子途径和机制起源转化为新型疗法的分子靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号